Article
A clinical trial of lovastatin for modification of biomarkers associated with breast cancer risk.
Breast cancer research and treatment - 1 Nov 2013
Vinayak Shaveta, Schwartz Erich J, Jensen Kristin, Lipson Jafi, Alli Elizabeth, McPherson Lisa, Fernandez Adrian M, Sharma Vandana B, Staton Ashley, Mills Meredith A, Schackmann Elizabeth A, Telli Melinda L, Kardashian Ani, Ford James M, Kurian Allison W
Abstract excerpt
Pre-clinical and epidemiologic studies provide rationale for evaluating lipophilic statins for breast cancer prevention. We conducted a single-arm, biomarker modulation trial of lovastatin among women with increased risk of breast cancer. Eligibility criteria included a deleterious germline mutation in BRCA1, BRCA2, CDH1, or TP53; lifetime breast cancer risk of ≥20 % as estimated by the Claus model; or personal...
Read the complete abstract on PubMedTopics
Share this publication in a Topic to start or enrich a Post.